elosulfase alfa

FDA Drug Profile — VIMIZIM

Drug Details

Generic Name
elosulfase alfa
Brand Names
VIMIZIM
Application Number
BLA125460
Sponsor
BioMarin International Limited
NDC Codes
3
Dosage Forms
INJECTION, SOLUTION, CONCENTRATE
Routes
INTRAVENOUS
Active Ingredients
ELOSULFASE ALFA

Indications and Usage

1 INDICATIONS AND USAGE VIMIZIM (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). VIMIZIM is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). ( 1 )